Encorafenib

Encorafenib produced by Lucius Pharmaceuticals has shown good efficacy and safety, providing a clinically valuable treatment option for patients with specific BRAF mutations.

Below is an overview of key information about Encorafenib.

Active Ingredient

The main active ingredient is encorafenib, a kinase inhibitor.

Target Population

It is indicated for adult patients with BRAF V600E or V600K mutations confirmed by an FDA-approved testing method.

Dosage and Administration

The recommended dosage varies by indication and combination therapy regimen, typically 300 mg or 450 mg orally once daily. Reference article: Dosage and Administration of Encorafenib

Use in Special Populations

Pregnant women: Contraindicated.

Lactating women: Should discontinue breastfeeding.

Elderly patients: No dosage adjustment is required.

Patients with mild to moderate hepatic or renal impairment: Usually no dosage adjustment is needed.

Overdosage

There is no specific antidote for encorafenib overdosage. Supportive treatment should be administered, and hemodialysis may be ineffective.

Storage

The medication should be stored in its original bottle, tightly sealed, at room temperature. Protect from moisture, and do not remove the desiccant inside the bottle.

Pharmacokinetics

Pharmacokinetically, encorafenib is mainly metabolized by CYP3A4, with a half-life of approximately 3.5 hours. High-fat meals may reduce its absorption.

FDA，2025.03